BNTX Quote, Financials, Valuation and Earnings

GSK Plc has a net margin of -33.61% compared to BioNTech SE's net margin of 8.44%. BioNTech SE's return on equity of -5.93% beat GSK Plc's return on equity of 43.01%.

BioNTech SE has a consensus price target of $130.51, signalling upside risk potential of 43.13%. On the other hand GSK Plc has an analysts' consensus of $57.48 which suggests that it could grow by 1.39%. Given that BioNTech SE has higher upside potential than GSK Plc, analysts believe BioNTech SE is more attractive than GSK Plc.

BioNTech SE has a beta of 1.581, which suggesting that the stock is 58.073% more volatile than S&P 500. In comparison GSK Plc has a beta of 0.482, suggesting its less volatile than the S&P 500 by 51.834%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GSK Plc offers a yield of 3.11% to investors and pays a quarterly dividend of $0.49 per share. BioNTech SE pays -- of its earnings as a dividend. GSK Plc pays out 47.15% of its earnings as a dividend. GSK Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BioNTech SE quarterly revenues are $1.1B, which are smaller than GSK Plc quarterly revenues of $11.5B. BioNTech SE's net income of -$355M is lower than GSK Plc's net income of $966.8M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while GSK Plc's PE ratio is 15.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 6.64x versus 2.70x for GSK Plc. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -33.61% compared to BioNTech SE's net margin of 18.15%. BioNTech SE's return on equity of -5.93% beat Merck & Co., Inc.'s return on equity of 36.76%.

BioNTech SE has a consensus price target of $130.51, signalling upside risk potential of 43.13%. On the other hand Merck & Co., Inc. has an analysts' consensus of $128.59 which suggests that it could grow by 6.11%. Given that BioNTech SE has higher upside potential than Merck & Co., Inc., analysts believe BioNTech SE is more attractive than Merck & Co., Inc..

BioNTech SE has a beta of 1.581, which suggesting that the stock is 58.073% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.446%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.74% to investors and pays a quarterly dividend of $0.85 per share. BioNTech SE pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BioNTech SE quarterly revenues are $1.1B, which are smaller than Merck & Co., Inc. quarterly revenues of $16.3B. BioNTech SE's net income of -$355M is lower than Merck & Co., Inc.'s net income of $3B. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Merck & Co., Inc.'s PE ratio is 16.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 6.64x versus 4.67x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -33.61% compared to BioNTech SE's net margin of -121.83%. BioNTech SE's return on equity of -5.93% beat Moderna, Inc.'s return on equity of -29.19%.

BioNTech SE has a consensus price target of $130.51, signalling upside risk potential of 43.13%. On the other hand Moderna, Inc. has an analysts' consensus of $43.75 which suggests that it could fall by -11.08%. Given that BioNTech SE has higher upside potential than Moderna, Inc., analysts believe BioNTech SE is more attractive than Moderna, Inc..

BioNTech SE has a beta of 1.581, which suggesting that the stock is 58.073% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.331, suggesting its more volatile than the S&P 500 by 33.144%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

BioNTech SE quarterly revenues are $1.1B, which are larger than Moderna, Inc. quarterly revenues of $678M. BioNTech SE's net income of -$355M is higher than Moderna, Inc.'s net income of -$826M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 6.64x versus 9.69x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novavax, Inc. has a net margin of -33.61% compared to BioNTech SE's net margin of 11.91%. BioNTech SE's return on equity of -5.93% beat Novavax, Inc.'s return on equity of --.

BioNTech SE has a consensus price target of $130.51, signalling upside risk potential of 43.13%. On the other hand Novavax, Inc. has an analysts' consensus of $13.78 which suggests that it could grow by 78.93%. Given that Novavax, Inc. has higher upside potential than BioNTech SE, analysts believe Novavax, Inc. is more attractive than BioNTech SE.

BioNTech SE has a beta of 1.581, which suggesting that the stock is 58.073% more volatile than S&P 500. In comparison Novavax, Inc. has a beta of 2.646, suggesting its more volatile than the S&P 500 by 164.551%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Novavax, Inc. pays out -- of its earnings as a dividend.

BioNTech SE quarterly revenues are $1.1B, which are larger than Novavax, Inc. quarterly revenues of $147.1M. BioNTech SE's net income of -$355M is lower than Novavax, Inc.'s net income of $17.5M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Novavax, Inc.'s PE ratio is 3.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 6.64x versus 1.13x for Novavax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.